Glut-1 Expression Correlates with Basal-like Breast Cancer

Translational Oncology

Volumn 4, Issue 6, 2011, Pages 321-327

  Hussein, Yaser R ^a   Bandyopadhyay, Sudeshna ^a   Semaan, Assaad ^a   Ahmed, Quratulain ^a   Albashiti, Bassam ^a   Jazaerly, Tarek ^a   Nahleh, Zeina ^a   Ali Fehmi, Rouba ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOSE TRANSPORTER 1; PROGESTERONE RECEPTOR; PROTEIN P53;

BREAST CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOLOGY; PROTEIN EXPRESSION; REVIEW; TISSUE MICROARRAY;

EID: 82855169091     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11256     Document Type: Review

References (46)

1. Brenton JD, Carey LA, Ahmed AA, and Caldas C (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29), 7350-7360.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human breast tumours. Nature 406(6797), 747-752.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14), 8418-8423.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19), 10869-10874.
5. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, and Ellis IO (2005). High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3), 340-350.
6. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, and Ellis IO (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2), 661-671.
7. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16), 5367-5374.
8. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, and Lewensohn R (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10), 1639-1646.
9. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, and Hanby A (2006). Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49(1), 22-34.
10. Matos I, Dufloth R, Alvarenga M, Zeferino LC, and Schmitt F (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447(4), 688-694.
11. Brown JM and Giaccia AJ (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58(7), 1408-1416.
12. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19), 4509-4515.
13. Semenza GL (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35(2), 71-103.
14. Behrooz A and Ismail-Beigi F (1997). Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem 272(9), 5555-5562.
15. Olson AL and Pessin JE (1996). Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16, 235-256.
16. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, et al. (2006). Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207(3), 614-627.
17. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, and Burstein DE (1998). GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83(1), 34-40.
18. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, and Suzuki T (2001). Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92(3), 634-641.
19. Younes M, Brown RW, Stephenson M, Gondo M, and Cagle PT (1997). Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80(6), 1046-1051.
20. Alò PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, Di Tondo U, and Pizer ES (2001). Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 116(1), 129-134.
21. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, and Hendrix MJ (1998). Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 4(2), 115-120.
22. Younes M, Brown RW, Mody DR, Fernandez L, and Laucirica R (1995). GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 15(6B), 2895-2898.
23. Elston CW and Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5), 403-410.
24. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, and Valenstein PN (2010). Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med 134, 930-935.
25. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1), 118-145.
26. Greene FL and American Joint Committee on Cancer (2002). AJCC Cancer Staging Manual (6th ed). Springer, New York, NY. xiv, p. 421.
27. Camp RL, Charette LA, and Rimm DL (2000). Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12), 1943-1949.
28. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, et al. (2009). GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 174(4), 1544-1552.
29. Younes M, Lechago LV, Somoano JR, Mosharaf M, and Lechago J (1996). Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 56(5), 1164-1167.
30. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, and Gilks CB (2004). Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 23(2), 129-137.
31. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492-2502.
32. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, and Bordoni A (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20(4), 628-635.
33. Isselbacher KJ (1972). Sugar and amino acid transport by cells in culturedifferences between normal and malignant cells. N Engl J Med 286(17), 929-933.
34. Merrall NW, Plevin R, and Gould GW (1993). Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 5(6), 667-675.
35. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, and Park YK (2002). Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 93(10), 1123-1128.
36. Schwartzenberg-Bar-Yoseph F, Armoni M, and Karnieli E (2004). The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64(7), 2627-2633.
37. van der Groep P, Bouter A, Menko FH, van der Wall E, and van Diest PJ (2008). High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 111(3), 475-480.
38. Chappuis PO, Nethercot V, and Foulkes WD (2000). Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer. Semin Surg Oncol 18(4), 287-295.
39. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, and Sobol H (1996). Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56(3), 471-474.
40. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, et al. (2004). The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascularproliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64(3), 830-835.
41. Corkery B, Crown J, Clynes M, and O'Donovan N (2009). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20(5), 862-867.
42. Finn RS, Bengala C, Ibrahim N, Strauss LC, Fairchild J, Sy O, Roché H, Sparano J, and Goldstein LJ (2008). Phase II trial of dasatinib in triplenegative breast cancer: results of study CA180059. Cancer Res 69(suppl), 242s. Abstract 3118.
43. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26), 2666-2676.
44. Rastogi S, Banerjee S, Chellappan S, and Simon GR (2007). Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 257(2), 244-251.
45. Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, et al. (2000). Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane 452 glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 18, 3535-3544.
46. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J, and Airley R (2008). Increased chemoresistance and HIF-1 independent link with cell turnover is revealed through COMPARE analysis and metabolic studies. Cancer Chemother Pharmacol 61, 377-393.